26 11, 2025

TAmiRNA and Orthopaedic Hospital Speising Publish Landmark Data on promiR® for Accurate Diagnosis of Periprosthetic Joint Infections

2025-11-26T09:49:12+01:00November 26th, 2025|biomarkers in orthopaedics, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, periprosthetic joint infections, promiR, quality, Synovial fluid|0 Comments

On November 19th, 2025, the study “Synovial Fluid MicroRNA Biomarkers Enable Accurate Diagnosis of Hip and Knee Periprosthetic Joint Infections” by Frank et al. was published in the Journal of Bone and Joint Surgery. This peer-reviewed publication marks an important milestone in TAmiRNA’s biomarker development program and presents promiR®, our novel microRNA-based diagnostic panel designed to improve the pre-operative assessment of periprosthetic joint infections (PJIs). Clinical Challenge PJIs remain one of the most serious and difficult complications following total joint replacement. Current diagnostic methods—including inflammatory markers, imaging, and cultures—often lack sensitivity and specificity, especially for low-grade or culture-negative infections. Even advanced approaches such as PCR or next-generation sequencing can suffer from contamination risks and ambiguous [...]

11 11, 2025

Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

2025-11-11T08:44:13+01:00November 11th, 2025|exosomes, extracellular vesicle, Illumina NewSeq2000, microRNA, microRNA services, miND, miND spike ins, miND spike-in, NGS, quality|Comments Off on Distinct microRNA profiles in human amniotic membrane its vesicular and non-vesicular secretome revealed

Vienna, Austria – November 2025 TAmiRNA scientist have contributed significantly to a new study published by the Ludwig Boltzmann Institute for Traumatology, which is titled “Distinct miRNA profiles in human amniotic tissue and its vesicular and non-vesicular secretome”. The article was published in Frontiers in Cell and Developmental Biology on October 29th 2025. Human amniotic membrane (hAM) has been used in tissue regeneration and wound healing applications. In this study, the miND® small RNA-sequencing workflow was applied to generate fresh insights into the microRNA composition of two spatially and physiologically distinct regions of the human amniotic membrane (hAM) and its secreted extracellular vesicles (EVs) and protein-bound miRNAs. The work highlights how advanced analytical workflows can uncover tissue- [...]

3 11, 2025

TAmiRNA launches the new lyophilized miND® spike-in kit for small RNA-sequencing quality control

2025-11-03T11:11:21+01:00November 3rd, 2025|miND, miND spike ins, miND spike-in, NGS, quality|Comments Off on TAmiRNA launches the new lyophilized miND® spike-in kit for small RNA-sequencing quality control

Vienna, Austria – November 2025 TAmiRNA proudly announces the release of its miND® spike-in kit in a new lyophilized format, optimized for the preparation and analysis of 96 small RNA-sequencing libraries. This upgraded format improves handling, stability, and integration with standard small RNA-sequencing workflows, ensuring seamless compatibility with commonly used library preparation kits. The new lyophilized miND® spike-in kit combines ease of use and long-term stability with TAmiRNA’s proven spike-in design (5’ and 3’ end randomization) for accurate and reproducible normalization in small RNA-sequencing experiments. The revised 96-reaction format is ideal for medium- to large-scale studies and simplifies quality control across multiple runs. In addition, TAmiRNA has generated new data confirming the robust performance and stability of [...]

9 01, 2025

TAmiRNA ‘2024 In Review’

2025-01-09T14:05:02+01:00January 9th, 2025|biomarker, Biomarker Discovery, biomarkers, CE-IVD, congress, EVscale, exosomes, extracellular vesicle, hepatomiR kit, Illumina NewSeq2000, ISO 13485, liquid biopsies, Liver disease, microRNA, microRNA services, microRNAs, NGS, PCR testing service, quality, sequencing, small RNA-sequencing, smallRNA, test service|Comments Off on TAmiRNA ‘2024 In Review’

2024: A Year of Growth, Innovation, and Collaboration 2024 has come to a close. We are proud to reflect on the milestones and achievements we’ve reached together with our incredible team, customers, partners, and supporters. Here’s a look back at what we accomplished this year: 👩‍🔬 Team Expansion Welcomed 3 talented new members to our growing team. 🏥 Diagnostic Implementation Successfully rolled out our CE-IVD microRNA liver function test in 5+ clinics, advancing molecular diagnostics. ✅ Service Excellence Completed over 80 RNA service projects, achieving 100% customer satisfaction. 🛠 Bioinformatics Innovation Developed 2 new pipelines: isomiR analysis and tRNA analysis, enhancing our capabilities. 🧬 Expanded Service Offerings Added whole-transcriptome sequencing for mRNA, lncRNA, and circRNA in liquid biopsies to our service portfolio. [...]

13 02, 2024

Webinar – COST Action AtheroNET

2024-02-13T11:20:12+01:00February 13th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on Webinar – COST Action AtheroNET

Looking forward to sharing our insights from 10+ years of extracellular microRNA (and recently long RNA as well) biomarker discovery and diagnostic test development with the COST Action AtheroNET group. Date: 19.02.2024 Time: 19:30 CET Registration Link: https://lnkd.in/dVDDYKcA Reach out to Matthias directly after his webinar and discuss our latest developments and how TAmiRNA’s  miND spike ins and small RNA sequencing service can assist your business!

26 01, 2024

TAmiRNA ‘2023 In Review’

2024-01-26T11:44:38+01:00January 26th, 2024|biomarker, biomarkers, exosomes, extracellular vesicle, ISO 13485, Liver disease, microRNA, microRNA services, microRNAs, quality, sequencing, smallRNA|Comments Off on TAmiRNA ‘2023 In Review’

One last look back at 2023 before we turn our attention to our goals for 2024: last year brought us progress in many areas, from the development of new laboratory and data analyses to the implementation of hepatomiR® in routine clinical diagnostics and the establishment of important partnerships. Our thanks go to the entire (growing) TAmiRNA team, and our customers and partners! We look forward to working together and to our joint successes in 2024!

31 01, 2023

We are proud to announce our ISO 13485:2016 certification

2023-03-10T08:28:14+01:00January 31st, 2023|biomarkers, ISO 13485, microRNA, quality, smallRNA|Comments Off on We are proud to announce our ISO 13485:2016 certification

Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our team to meet customer and international regulatory expectations," said Matthias Hackl, Co-Founder and CEO of TAmiRNA. ISO 13485:2016 is an internationally recognized quality systems standard tailored to the development and manufacturing of medical devices, including in-vitro diagnostic tests. This certification represents an important milestone for our company, and reflects our rigorous and risk-based approach [...]

Go to Top